Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL VII: IDegLira versus basal-bolus therapy in adults with type 2 diabetes mellitus
2014-003621-18Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c. Started Mar 2015; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-003621-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003621-18.